Biomarkers for immune intervention trials in type 1 diabetes. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical Immunology Year : 2013

Biomarkers for immune intervention trials in type 1 diabetes.


After many efforts to improve and standardize assays for detecting immune biomarkers in type 1 diabetes (T1D), methods to identify and monitor such correlates of insulitis are coming of age. The ultimate goal is to use these correlates to predict disease progression before onset and regression following therapeutic intervention, which would allow performing smaller and shorter pilot clinical trials with earlier endpoints than those offered by preserved β-cell function or improved glycemic control. Here, too, progress has been made. With the emerging insight that T1D represents a heterogeneous disease, the next challenge is to define patient subpopulations that qualify for personalized medicine or that should be enrolled for immune intervention, to maximize clinical benefit and decrease collateral damage by ineffective or even adverse immune therapeutics. This review discusses the current state of the art, setting the stage for future efforts to monitor disease heterogeneity, progression and therapeutic intervention in T1D.


Fichier principal
Vignette du fichier
Clin_Immunol_Review_HAL_version.pdf (275.22 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00806093 , version 1 (29-03-2013)



Roberto Mallone, Bart O. Roep. Biomarkers for immune intervention trials in type 1 diabetes.. Clinical Immunology, 2013, epub ahead of print. ⟨10.1016/j.clim.2013.02.009⟩. ⟨inserm-00806093⟩
224 View
422 Download



Gmail Facebook X LinkedIn More